Browsing by Author Feld, J.J., Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, Toronto, ON, Canada; Jacobson, I.M., Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA; Jensen, D.M., Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA; Foster, G.R., Queen Mary, University of London, Institute of Cellular and Molecular Sciences, London, UK; Pol, S., Hoˆpital Cochin, Universite´ Paris Descartes and INSERM U1610, Paris, France; Tam, E., LAIR Centre, Vancouver, BC, Canada; Jablkowski, M., Medical University of Lodz, Lodz, Poland; Berak, H., Hospital of Infectious Diseases, Warsaw, Poland; Vierling, J.M., Baylor College of Medicine, Houston, TX, USA; Yoshida, E.M., University of British Columbia, Vancouver, BC, Canada; Perez-Gomez, H.R., Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa, Universidad de Guadalajara, Guadalajara, Mexico; Scalori, A., Roche Products Ltd, Welwyn, UK; Hooper, G.J., Roche Products Ltd, Welwyn, UK; Tavel, J.A., Genentech, South San Francisco, CA, USA; Navarro, M.T., Genentech, South San Francisco, CA, USA; Shahdad, S., Roche Products Ltd, Welwyn, UK; Kulkarni, R., Genentech, South San Francisco, CA, USA; Pogam, S.L., Hoffmann-La Roche Inc, Nutley, NJ, USA; Nájera, I., F. Hoffmann-La Roche Ltd, Basel, Switzerland; Eng, S., Genentech, South San Francisco, CA, USA; Lim, C.Y., Genentech, South San Francisco, CA, USA; Shulman, N.S., Genentech, South San Francisco, CA, USA; Yetzer, E.S., Genentech, South San Francisco, CA, USA

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 1 of 1
Issue DateTitleAuthor(s)
2014Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinFeld, J.J.; Jacobson, I.M.; Jensen, D.M.; Foster, G.R.; Pol, S.; Tam, E.; Jablkowski, M.; Berak, H.; Vierling, J.M.; Yoshida, E.M.; Perez-Gomez, H.R.; Scalori, A.; Hooper, G.J.; Tavel, J.A.; Navarro, M.T.; Shahdad, S.; Kulkarni, R.; Pogam, S.L.; Najera, I.; Eng, S.; Lim, C.Y.; Shulman, N.S.; Yetzer, E.S.; Feld, J.J., Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, Toronto, ON, Canada; Jacobson, I.M., Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA; Jensen, D.M., Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA; Foster, G.R., Queen Mary, University of London, Institute of Cellular and Molecular Sciences, London, UK; Pol, S., Hoˆpital Cochin, Universite´ Paris Descartes and INSERM U1610, Paris, France; Tam, E., LAIR Centre, Vancouver, BC, Canada; Jablkowski, M., Medical University of Lodz, Lodz, Poland; Berak, H., Hospital of Infectious Diseases, Warsaw, Poland; Vierling, J.M., Baylor College of Medicine, Houston, TX, USA; Yoshida, E.M., University of British Columbia, Vancouver, BC, Canada; Perez-Gomez, H.R., Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa, Universidad de Guadalajara, Guadalajara, Mexico; Scalori, A., Roche Products Ltd, Welwyn, UK; Hooper, G.J., Roche Products Ltd, Welwyn, UK; Tavel, J.A., Genentech, South San Francisco, CA, USA; Navarro, M.T., Genentech, South San Francisco, CA, USA; Shahdad, S., Roche Products Ltd, Welwyn, UK; Kulkarni, R., Genentech, South San Francisco, CA, USA; Pogam, S.L., Hoffmann-La Roche Inc, Nutley, NJ, USA; Nájera, I., F. Hoffmann-La Roche Ltd, Basel, Switzerland; Eng, S., Genentech, South San Francisco, CA, USA; Lim, C.Y., Genentech, South San Francisco, CA, USA; Shulman, N.S., Genentech, South San Francisco, CA, USA; Yetzer, E.S., Genentech, South San Francisco, CA, USA